Genfit Positions To Battle Intercept On Both NASH And PBC Fronts
This article was originally published in The Pink Sheet Daily
Executive Summary
While beginning to enroll the Phase III trial of elafibranor in NASH, Genfit also plans to study the drug in PBC, an indication in which top competitor Intercept could receive FDA approval this quarter.
You may also be interested in...
Genfit Says Safety/Tolerability Will Give Elafibranor An Edge In NASH
Lack of pruritus and a positive cardiometabolic profile could give elafibranor an advantage as it competes with Intercept’s Ocaliva to be the first drug therapy to market in NASH. The French biotech also is working on a biomarker algorithm to optimize patient selection.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.